Description

Mechanism of Action
Semaglutide mimics the activity of the natural incretin hormone GLP-1, binding to GLP-1
receptors throughout the pancreas, gastrointestinal tract, and central nervous system. By
activating these receptors.
Enhances glucose-dependent insulin secretion from pancreatic β-cells while suppressing
inappropriate glucagon release, leading to more stable blood glucose levels.
Delays gastric emptying, supporting improved satiety and reduced postprandial glucose
excursions.
Acts on appetite-regulating centers in the brain to decrease hunger and caloric intake, aiding in
weight management and improved metabolic balance.
Through these coordinated actions, Semaglutide addresses key mechanisms of metabolic
dysfunction and supports long-term metabolic health, making it a cornerstone therapy in modern
weight and glucose management strategies.

Key Benefits

• Sustained Appetite Regulation: Semaglutide slows gastric emptying and reduces appetite,
  promoting consistent calorie reduction and weight loss.
• Enhanced Glycemic Control: Improves fasting and postprandial glucose levels by increasing
  glucose-dependent insulin secretion and reducing glucagon release.
• Support for Lean Mass Preservation: Glycine contributes to muscle maintenance and may help
  counteract loss of lean tissue during significant weight reduction.
• Improved Metabolic Efficiency: May enhance insulin sensitivity and support long-term
  metabolic resilience.
• Convenient Dosing: Once-weekly injection schedule supports patient adherence and simplifies
• Comprehensive Weight Management: Targets both metabolic pathways and body composition
  for more balanced outcomes compared to GLP-1 therapy alone.